Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
benzylthiouracil
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Benzylthiouracil is a small molecule antithyroid drug of the thioamide class, closely related to propylthiouracil. It acts by inhibiting thyroid peroxidase, thereby blocking the synthesis of thyroid hormones (T3 and T4) but not their release. This leads to a reduction in circulating thyroid hormone levels once preformed stores are depleted. Benzylthiouracil is primarily indicated for the treatment of hyperthyroidism and multinodular goiter. The drug has been associated with severe adverse effects, including vasculitis (notably ANCA-positive glomerulonephritis), toxic hepatitis, and lung damage[1][4][5].
- Other names
- 6-benzyl-2-thiouracil
02
Targets
TPO (Thyroid peroxidase)
Beyond the preview
Go deeper on benzylthiouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on benzylthiouracil.